FibroGen, Inc.

Refoxy Pharma secures $9.58 million to develop IPF drug RP-01 targeting FOXO3. Boehringer Ingelheim plans NDA submission for nerandomilast. Insilico's ISM001-055 and Endeavor's ENV-101 show disease improvement. Vicore's buloxibutid and BMS' BMS-986278 also chart progress. Pliant's bexotegrast mitigates chronic cough in IPF. IPOs and partnerships fuel IPF therapeutic field.

AffyImmune Therapeutics appoints Deyaa Adib, M.D., as Chief Medical Officer, bringing 28 years of oncology experience. Adib will oversee clinical activities, including strategic direction and execution of development programs. He has led successful registrations in solid tumor and hematologic malignancy indications and has held CMO roles at FibroGen, Triumvira Immunologics, Rain Therapeutics, and Blueprint Medicines.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

DelveInsight's 'Duchenne Muscular Dystrophy (DMD) Pipeline Insight, 2024' analyzes over 75 pipeline drugs from 75+ companies, focusing on recent FDA, EMA, and PMDA approvals, clinical trials, emerging therapies, and key players like Roche, Santhera, and Sarepta. The report covers various stages of development, routes of administration, and mechanisms of action, offering insights into the evolving DMD therapeutics landscape.

Vir Biotechnology lays off 141 employees, FibroGen cuts 75% of U.S. workforce. A new private school, Hiba Academy, opens in Airbnb’s former SF HQ. Silver Crest Donut Shop, known for its 24/7 service, permanently closes.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.